Hypoxia Activated Prodrugs

One step 2-nitroimidazole active site capping of commercialized compound.

Advantage & Core Benefits

  • Much higher tolerability with reduced toxicity.
  • Synergetic effects with radiation therapy confirmed by Gemcitabine, PARP, CDK4/6 inhibitors.
  • Prodrugs of three classic chemotherapy compounds are registered-patent protected.

Background & Technology

Although chemotherapies are commonly prescribed to kinds of tumors, severe adverse effects owing to the toxicity to normal dividing cells limit the doses and efficacies. And those drugs cannot reach hypoxic regions of tumor, which could be one of the reasons that cancers acquire drug resistance, abilities of invasion and metastasis.
The novel hypoxia-activated prodrugs are engineered with nitro-imidazole derivative, which are designed to seal the toxicity in normoxic condition, selectively distribute to hypoxic region of tumor and are activated.

 5Fluo 1

Data

  • 5-FU, Doxorubicin(Dox), Gemcitabine(Gem), Niraparib(PARP), Panobinostat/Entinostat(HDAC), Crizotinib /Ceritinib(ALK/ROS), Cobimetinib(MEK), Dabrafenib/Vemurafenib(BRAF), Palbociclib/ribociclib(CDK) have shown to be applicable.
  • Combination effect with Radiation Therapy was confirmed by Gem(Fig), and other compounds.

Patent

Dox, Gem, 5-FU product registered: 9655975(US), 2816036 (EP), 5676020 (JP)

Radiation combination therapy: WO2023/120331

Researchers

Dr. Yutaka Ikeda and Dr. Yukio Nagasaki (University of Tsukuba)

Expectations

We are seeking companies who are interested in in-licensing and commercialization.
Other than HAPs already created, applicability study for other molecules are welcome.
Samples are available under material transfer agreement.

Product No:KJ-02445

 

 

Medicine

Updated
Published

Inquiry Form

    Your name (*required)

    E-mail address (*required)

    Company name

    Message (*required)

    Following submission of your inquiry

    We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.

    <Notice>


    Our support is provided free of charge.
    The information submitted on this form is for business development use only.


    By clicking "Send", you are agreeing to our Privacy Policy.
    If you have questions please reach out to info (at) tech-manage.co.jp.

    About Bionauts.jp Tech Manage Corp.
    Copyright © Tech Manage Corp. All Rights Reserved.
    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.